Results 21 to 30 of about 99,201 (311)
MUC1 in hematological malignancies [PDF]
Leukemia & Lymphoma, 2016 Mucin1 (MUC1) is a transmembrane oncogenic protein that plays a central role in malignant transformation and disease evolution, including cell proliferation, survival, self-renewal, and metastatic invasion. MUC1 has been shown to interact with diverse effectors such as β-catenin, receptor tyrosine kinases, and c-Abl, which are of importance in the ...
Dina, Stroopinsky +2 more
openaire +2 more sources
Advances in Hematologic Malignancies [PDF]
, 2019 The book Advances in Hematologic Malignancies presents new knowledge of cellular disease processes, molecular pathology, and cytogenetic, epigenetic, and genomic changes that have influenced the current outlook toward hematological malignancies.
core +1 more source
Chromosomal in situ suppression hybridization of immunologically classified mitotic cells in hematologic malignancies [PDF]
, 1992 Chromosomal in situ suppression (CISS) hybridization was performed with library DNA from sorted human chromosomes 8, 9, 15, 17, 21, and 22 on immunologically stained bone marrow cells of four patients with a hematologic neoplasm, including two patients ...
Knuutila, Sakari +15 more
core +1 more source
Elotuzumab as a novel anti-myeloma immunotherapy
Human Vaccines & Immunotherapeutics, 2017 Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches.
Sabarinath Venniyil Radhakrishnan +5 more
doaj +1 more source
Current Oncology, 2023 Mitophagy plays an important role in maintaining mitochondrial homeostasis by clearing damaged mitochondria. Sphingosine kinase 2 (SK2), a type of sphingosine kinase, is an important metabolic enzyme involved in generating sphingosine-1-phosphate.
Jian Wu +5 more
doaj +1 more source
Frontiers in Immunology, 2022 BackgroundNatural killer (NK) cells play a vital role in early immune reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT).MethodsA literature search was performed on PubMed, Cochrane, and Clinical trials.gov through April ...
Muhammad Umair Mushtaq +16 more
doaj +1 more source
Immune Therapies for Hematologic Malignancies
, 2021 The era of immunotherapy for hematologic malignancies began with the first allogeneic hematopoietic stem cell transplant (HSCT) study published by E [...
Matthew J. Olnes
core +1 more source
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
OncoImmunology, 2017 Treatment for multiple myeloma (MM) has significantly advanced in the last decade with the introduction of proteasome inhibitors and immunomodulatory therapies.
Sabarinath Venniyil Radhakrishnan +3 more
doaj +1 more source
mTOR regulation of metabolism in hematologic malignancies [PDF]
, 2020 Neoplastic cells rewire their metabolism, acquiring a selective advantage over normal cells and a protection from therapeutic agents. The mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular activities ...
Simone Mirabilii +2 more
core +1 more source
Malignant benign hematology [PDF]
Research and Practice in Thrombosis and Haemostasis, 2019 When faced with a life-threatening non-cancerous blood disorder, the term "benign" is a misnomer. Devastating diseases like catastrophic antiphospholipid antibody syndrome, acquired hemophilia, and severe immune thrombocytopenia present a challenge to the hematologist.
openaire +2 more sources